Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes

AIM: To report real-life data on the use of an intravitreal fluocinolone acetonide implant in the treatment of refractory diabetic macular edema (DME) in pars plana vitrectomized (PPV) and non-PPV eyes. METHODS: This was a comparative retrospective observational study of 23 eyes with chronic DME. B...

Full description

Bibliographic Details
Main Authors: Alberto La Mantia, Alan Hawrami, Heidi Laviers, Sudeshna Patra, Hadi Zambarakji
Format: Article
Language:English
Published: Press of International Journal of Ophthalmology (IJO PRESS) 2018-12-01
Series:International Journal of Ophthalmology
Subjects:
Online Access:http://www.ijo.cn/en_publish/2018/12/20181213.pdf
id doaj-bb40d69dad644f13b2bb029d12430f19
record_format Article
spelling doaj-bb40d69dad644f13b2bb029d12430f192020-11-25T00:37:55ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982018-12-0111121951195610.18240/ijo.2018.12.13Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyesAlberto La Mantia0Alan Hawrami1Heidi Laviers2Sudeshna Patra3Hadi Zambarakji4Eye Treatment Centre, Whipps Cross University Hospital, Barts Health National Health System Foundation Trust, Leytonstone, London E11 1NR, UKEye Treatment Centre, Whipps Cross University Hospital, Barts Health National Health System Foundation Trust, Leytonstone, London E11 1NR, UKEye Treatment Centre, Whipps Cross University Hospital, Barts Health National Health System Foundation Trust, Leytonstone, London E11 1NR, UKEye Treatment Centre, Whipps Cross University Hospital, Barts Health National Health System Foundation Trust, Leytonstone, London E11 1NR, UKEye Treatment Centre, Whipps Cross University Hospital, Barts Health National Health System Foundation Trust, Leytonstone, London E11 1NR, UKAIM: To report real-life data on the use of an intravitreal fluocinolone acetonide implant in the treatment of refractory diabetic macular edema (DME) in pars plana vitrectomized (PPV) and non-PPV eyes. METHODS: This was a comparative retrospective observational study of 23 eyes with chronic DME. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded at baseline, 1, 4 and 12mo. Descriptive statistics and non-parametric tests were performed to analyze and compare PPV and non-PPV eyes. RESULTS: Seven PPV and 16 non-PPV eyes were included in the study. Median BCVA in the non-PPV group varied from 0.65 logMAR [Interquartile range (IQR): 0.40] at baseline to 0.42 logMAR (IQR: 0.40) at 12mo. Median CMT varied from 430 µm (IQR: 131.3) at baseline to 317 µm (IQR: 107.5) at 12mo. Median BCVA in the PPV group varied from 0.60 logMAR (IQR: 0.62) at baseline to 0.74 logMAR (IQR: 0.34) at 12mo. Median CMT varied from 483 µm (IQR: 146) at baseline to 397 µm (IQR: 132) at 12mo. Of 0/7 eyes and 1/16 eyes in the PPV and non-PPV eyes respectively had a baseline visual acuity of 6/12 or better (0.3 logMAR). At last follow up, 1/7 and 5/16 eyes in the PPV and non-PPV group respectively achieved a visual acuity of 6/12 or better. CONCLUSION: Visual outcomes are modest following the use of the fluocinolone acetonide implant for chronic DME. The steroid implant is a useful treatment option in the management of refractory DME in vitrectomized and non-vitrectmized eyes.http://www.ijo.cn/en_publish/2018/12/20181213.pdfdiabetic macular edemafluocinolone acetonideintravitreal implantsteroidvitrectomy
collection DOAJ
language English
format Article
sources DOAJ
author Alberto La Mantia
Alan Hawrami
Heidi Laviers
Sudeshna Patra
Hadi Zambarakji
spellingShingle Alberto La Mantia
Alan Hawrami
Heidi Laviers
Sudeshna Patra
Hadi Zambarakji
Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes
International Journal of Ophthalmology
diabetic macular edema
fluocinolone acetonide
intravitreal implant
steroid
vitrectomy
author_facet Alberto La Mantia
Alan Hawrami
Heidi Laviers
Sudeshna Patra
Hadi Zambarakji
author_sort Alberto La Mantia
title Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes
title_short Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes
title_full Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes
title_fullStr Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes
title_full_unstemmed Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes
title_sort treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes
publisher Press of International Journal of Ophthalmology (IJO PRESS)
series International Journal of Ophthalmology
issn 2222-3959
2227-4898
publishDate 2018-12-01
description AIM: To report real-life data on the use of an intravitreal fluocinolone acetonide implant in the treatment of refractory diabetic macular edema (DME) in pars plana vitrectomized (PPV) and non-PPV eyes. METHODS: This was a comparative retrospective observational study of 23 eyes with chronic DME. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded at baseline, 1, 4 and 12mo. Descriptive statistics and non-parametric tests were performed to analyze and compare PPV and non-PPV eyes. RESULTS: Seven PPV and 16 non-PPV eyes were included in the study. Median BCVA in the non-PPV group varied from 0.65 logMAR [Interquartile range (IQR): 0.40] at baseline to 0.42 logMAR (IQR: 0.40) at 12mo. Median CMT varied from 430 µm (IQR: 131.3) at baseline to 317 µm (IQR: 107.5) at 12mo. Median BCVA in the PPV group varied from 0.60 logMAR (IQR: 0.62) at baseline to 0.74 logMAR (IQR: 0.34) at 12mo. Median CMT varied from 483 µm (IQR: 146) at baseline to 397 µm (IQR: 132) at 12mo. Of 0/7 eyes and 1/16 eyes in the PPV and non-PPV eyes respectively had a baseline visual acuity of 6/12 or better (0.3 logMAR). At last follow up, 1/7 and 5/16 eyes in the PPV and non-PPV group respectively achieved a visual acuity of 6/12 or better. CONCLUSION: Visual outcomes are modest following the use of the fluocinolone acetonide implant for chronic DME. The steroid implant is a useful treatment option in the management of refractory DME in vitrectomized and non-vitrectmized eyes.
topic diabetic macular edema
fluocinolone acetonide
intravitreal implant
steroid
vitrectomy
url http://www.ijo.cn/en_publish/2018/12/20181213.pdf
work_keys_str_mv AT albertolamantia treatmentofrefractorydiabeticmacularedemawithafluocinoloneacetonideimplantinvitrectomizedandnonvitrectomizedeyes
AT alanhawrami treatmentofrefractorydiabeticmacularedemawithafluocinoloneacetonideimplantinvitrectomizedandnonvitrectomizedeyes
AT heidilaviers treatmentofrefractorydiabeticmacularedemawithafluocinoloneacetonideimplantinvitrectomizedandnonvitrectomizedeyes
AT sudeshnapatra treatmentofrefractorydiabeticmacularedemawithafluocinoloneacetonideimplantinvitrectomizedandnonvitrectomizedeyes
AT hadizambarakji treatmentofrefractorydiabeticmacularedemawithafluocinoloneacetonideimplantinvitrectomizedandnonvitrectomizedeyes
_version_ 1725298939259781120